IL159627A0 - T-cell regulatory genes and diagnostic methods utilizing the same - Google Patents

T-cell regulatory genes and diagnostic methods utilizing the same

Info

Publication number
IL159627A0
IL159627A0 IL15962702A IL15962702A IL159627A0 IL 159627 A0 IL159627 A0 IL 159627A0 IL 15962702 A IL15962702 A IL 15962702A IL 15962702 A IL15962702 A IL 15962702A IL 159627 A0 IL159627 A0 IL 159627A0
Authority
IL
Israel
Prior art keywords
same
diagnostic methods
methods utilizing
regulatory genes
cell regulatory
Prior art date
Application number
IL15962702A
Other languages
English (en)
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of IL159627A0 publication Critical patent/IL159627A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15962702A 2001-06-29 2002-07-01 T-cell regulatory genes and diagnostic methods utilizing the same IL159627A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30234401P 2001-06-29 2001-06-29
PCT/US2002/020890 WO2003002722A2 (en) 2001-06-29 2002-07-01 T cell regulatory genes and methods of use thereof

Publications (1)

Publication Number Publication Date
IL159627A0 true IL159627A0 (en) 2004-06-01

Family

ID=23167357

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15962702A IL159627A0 (en) 2001-06-29 2002-07-01 T-cell regulatory genes and diagnostic methods utilizing the same

Country Status (11)

Country Link
US (2) US7553939B2 (enExample)
EP (1) EP1406653A4 (enExample)
JP (3) JP4572276B2 (enExample)
KR (1) KR20040014997A (enExample)
CN (1) CN1538853A (enExample)
CA (1) CA2452196A1 (enExample)
IL (1) IL159627A0 (enExample)
MX (1) MXPA04000034A (enExample)
NZ (1) NZ530451A (enExample)
WO (1) WO2003002722A2 (enExample)
ZA (1) ZA200400013B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258793T5 (es) * 1996-05-24 2010-01-25 Biogen Idec Ma Inc. Moduladores de la regeneracion tisular.
NZ523475A (en) * 2000-06-16 2004-09-24 Biogen Inc Renal regulatory elements and methods of use thereof
JP4527394B2 (ja) * 2001-06-01 2010-08-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｋｉｍ−１の分断を阻害するための分子および方法
US8709412B2 (en) * 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
MXPA04000034A (es) * 2001-06-29 2005-11-23 Univ Leland Stanford Junior Genes regulatorios de celulas t metodos para utilizar los mismos.
JP4694128B2 (ja) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
EP1576169B1 (en) * 2002-03-19 2016-08-10 Celldex Therapeutics, Inc. Therapeutic polypeptides and methods of use
PT1585546E (pt) * 2002-12-30 2008-11-14 Biogen Idec Inc Antagonistas de kim-1 e sua utilização para modular o sistema imunitário
AU2004224390A1 (en) * 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
AU2013242840B2 (en) * 2003-03-19 2017-01-19 Amgen Fremont Inc. Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof
KR20060089732A (ko) 2003-10-03 2006-08-09 브라이엄 앤드 위민즈 하스피틀 Ｔｉｍ-3 리간드 및 그의 방법
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
AU2005231685A1 (en) * 2004-03-24 2005-10-20 Telos Pharmaceuticals Llc Compositions as adjuvants to improve immune responses to vaccines and methods of use
US7888010B2 (en) 2004-05-28 2011-02-15 Asuragen, Inc. Methods and compositions involving microRNA
EP2808389A1 (en) 2004-11-12 2014-12-03 Asuragen, Inc. Methods and compositions involving MIRNA and MIRNA inhibitor molecules
CN1778816B (zh) * 2004-11-22 2010-07-07 中国人民解放军第二军医大学 人细胞表面膜分子及用途
AU2006218489B2 (en) * 2005-03-02 2011-02-24 Biogen Ma Inc. KIM-1 antibodies for treatment of Th2-mediated conditions
KR100746312B1 (ko) * 2005-03-14 2007-08-03 한국화학연구원 수용성 산화철 나노 입자 및 이의 제조방법
JP5520605B2 (ja) * 2006-09-19 2014-06-11 アシュラジェン インコーポレイテッド 膵臓疾患で差次的に発現されるマイクロｒｎａおよびその使用
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
EP2268832A2 (en) * 2008-03-06 2011-01-05 Asuragen, INC. Microrna markers for recurrence of colorectal cancer
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
JP5800299B2 (ja) * 2009-02-20 2015-10-28 国立大学法人 東京大学 新規モノクローナル抗体、並びにその使用
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
JP6196034B2 (ja) * 2012-12-20 2017-09-13 ライオン株式会社 高血糖リスク判定用マーカーペプチドおよびその用途
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
PT3283508T (pt) * 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
TWI726920B (zh) * 2015-10-14 2021-05-11 耶魯大學 基因體規模的ｔ細胞活性陣列、其製造方法、其用於辨識免疫調節因子的方法及其用途
AU2017250358B2 (en) 2016-04-15 2023-06-01 Alpine Immune Sciences, Inc. ICOS ligand variant immunomodulatory proteins and uses thereof
KR20230091191A (ko) 2016-05-27 2023-06-22 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
SG10201911972QA (en) 2016-07-14 2020-02-27 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
EP3970749A1 (en) * 2016-08-26 2022-03-23 BeiGene, Ltd. Anti-tim-3 antibodies and use thereof
ES2912269T3 (es) 2016-09-27 2022-05-25 Cero Therapeutics Inc Moléculas de receptor de engullimiento quimérico
WO2018086594A1 (en) 2016-11-11 2018-05-17 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tim-3
EP3725327A3 (en) * 2017-04-10 2021-01-20 Immatics Biotechnologies GmbH Peptides and combination thereof for use in the immunotherapy against cancers
CA3073421A1 (en) 2017-09-26 2019-04-04 Daniel Mark COREY Chimeric engulfment receptor molecules and methods of use
CN108037292A (zh) * 2017-11-29 2018-05-15 天津市湖滨盘古基因科学发展有限公司 一种人的磷脂酰丝氨酸受体突变蛋白及其应用
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
JP7444781B2 (ja) 2018-03-28 2024-03-06 セロ・セラピューティクス・インコーポレイテッド 細胞免疫療法組成物およびその使用
CN110412263B (zh) * 2019-07-31 2023-01-31 中国农业科学院茶叶研究所 一种快速高效的茶树质体型谷氨酰胺合成酶基因定位方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
ES2258793T5 (es) * 1996-05-24 2010-01-25 Biogen Idec Ma Inc. Moduladores de la regeneracion tisular.
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
JP2002501738A (ja) * 1998-01-30 2002-01-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ６７個のヒト分泌タンパク質
DE69938293T2 (de) * 1998-03-27 2009-03-12 Bruce J. Beverly Hills Bryan Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose
WO2002081517A2 (en) 2001-01-19 2002-10-17 Curagen Corporation Novel polypeptides and nucleic acids encoded thereby
MXPA04000034A (es) * 2001-06-29 2005-11-23 Univ Leland Stanford Junior Genes regulatorios de celulas t metodos para utilizar los mismos.

Also Published As

Publication number Publication date
WO2003002722A3 (en) 2003-04-03
NZ530451A (en) 2008-04-30
JP2007000146A (ja) 2007-01-11
JP4572276B2 (ja) 2010-11-04
JP2010057492A (ja) 2010-03-18
US7553939B2 (en) 2009-06-30
EP1406653A4 (en) 2005-05-04
WO2003002722A2 (en) 2003-01-09
ZA200400013B (en) 2006-05-31
US20030124114A1 (en) 2003-07-03
JP4351233B2 (ja) 2009-10-28
EP1406653A2 (en) 2004-04-14
US20090252737A1 (en) 2009-10-08
CA2452196A1 (en) 2003-01-09
MXPA04000034A (es) 2005-11-23
WO2003002722A9 (en) 2004-04-15
CN1538853A (zh) 2004-10-20
KR20040014997A (ko) 2004-02-18
JP2005500039A (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
IL159627A0 (en) T-cell regulatory genes and diagnostic methods utilizing the same
AU2002327185A8 (en) Diagnostic methods and devices
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
GB0109537D0 (en) Well treatment fluids and methods for the use thereof
EP1425066A4 (en) Defibrillators
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002367856A8 (en) Diagnostic device
AU2002367971A8 (en) Continuously operational diagnostic device
GB2378490B (en) Differential device
GB9926805D0 (en) Diagnostic methods
GB2380234B (en) Differential device
GB0120009D0 (en) Cause and effect diagnosis
EP1367123A4 (en) NEUROTONIN AND ITS USE
GB0101086D0 (en) The sterile pack
PL354184A1 (en) The prv-1 gene and use thereof
AP2003002923A0 (en) Viral drug susceptibility testing.
GB9924717D0 (en) Diagnostic
AU2002364385A8 (en) Implantable device and the use thereof
GB0122410D0 (en) Cancer diagnosis
GB0123430D0 (en) GSPD`s
GB0118312D0 (en) Diagnostic
GB0122643D0 (en) Mbm
GB0202562D0 (en) Diagnosis
GB0105742D0 (en) Complexes and their use
AUPR596501A0 (en) Diagnostic methods and agents